Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-10-2014 | Original Paper

Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors

Authors: Florian Seemüller, Sebastian Meier, Michael Obermeier, Richard Musil, Michael Bauer, Mazda Adli, Klaus Kronmüller, Florian Holsboer, Peter Brieger, Gerd Laux, Wolfram Bender, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Michael Riedel, Peter Falkai, Hans-Jürgen Möller

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2014

Abstract

In randomized controlled trials, maintenance treatment for relapse prevention has been proven to be efficacious in patients responding in acute treatment, its efficacy in long-term outcome in “real-world patients” has yet to be proven. Three-year long-term data from a large naturalistic multisite follow-up were presented. Severe relapse was defined as suicide, severe suicide attempt, or rehospitalization. Next to relapse rates, possible risk factors including antidepressant medication were identified using univariate generalized log-rank tests and multivariate Cox proportional hazards model for time to severe relapse. Overall data of 458 patients were available for analysis. Of all patients, 155 (33.6 %) experienced at least one severe relapse during the 3-year follow-up. The following variables were associated with a shorter time to a severe relapse in univariate and multivariate analyses: multiple hospitalizations, presence of avoidant personality disorder, continuing antipsychotic medication, and no further antidepressant treatment. In comparison with other studies, the observed rate of severe relapse during 3-year period is rather low. This is one of the first reports demonstrating a beneficial effect of long-term antidepressant medication on severe relapse rates in naturalistic patients. Concomitant antipsychotic medication may be a proxy marker for treatment resistant and psychotic depression.

Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661. doi:10.1016/S0140-6736(03)12599-8 PubMedCrossRef

Posternak MA, Zimmerman M, Keitner GI, Miller IW (2002) A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 159:191–200PubMedCrossRef

Solomon DA, Leon AC, Endicott J et al (2004) Psychosocial impairment and recurrence of major depression. Compr Psychiatry 45:423–430. doi:10.1016/j.comppsych.2004.07.002 PubMedCrossRef

Hughes S, Cohen D (2009) A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord 118:9–18. doi:10.1016/j.jad.2009.01.027 PubMedCrossRef

Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR (2007) Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin Biochem 40:1026–1031PubMedCrossRef

Lin C-H, Chen M-C, Chou L-S et al (2010) Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatry Res 180:74–79. doi:10.1016/j.psychres.2009.12.003 PubMedCrossRef

Lin C-H, Chen Y-S, Lin C-H, Lin K-S (2007) Factors affecting time to rehospitalization for patients with major depressive disorder. Psychiatry Clin Neurosci 61:249–254. doi:10.1111/j.1440-1819.2007.01662.x PubMedCrossRef

Lin C-H, Lin K-S, Lin C-Y et al (2008) Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. J Clin Psychiatry 69:54–59PubMedCrossRef

Lin EH, Katon WJ, VonKorff M et al (1998) Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 7:443–449PubMedCrossRef

10.

Berto P, D’Ilario D, Ruffo P et al (2000) Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 3:3–10PubMedCrossRef

11.

Seemüller F, Riedel M, Obermeier M et al (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 20:346–355. doi:10.1016/j.euroneuro.2009.11.011 PubMedCrossRef

12.

Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997) Strukturiertes Klinisches Interview für DSM-IV. Hogrefe, Göttingen

13.

Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296PubMedCrossRef

14.

Cording C, Gaebel W, Spengler A (1995) Die neue psychiatrische Basisdokumentation. Eine Empfehlung der DGPPN zur Qualit„tssicherung im (teil-) station„ren Bereich. [The new psychiatric basic documentation. A recommendation by the DGPPN for quality assurance in inpatient treatment]. Spektrum Psychiatr Nervenheilkd 24:3–41

15.

Bauer M, Bschor T, Pfennig A et al (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104PubMedCrossRef

16.

Riedel M, Moller HJ, Obermeier M et al (2010) Response and remission criteria in major depression—a validation of current practice. J Psychiatr Res 44:1063–1068PubMedCrossRef

17.

R Foundation for Statistical Computing (2012) R: a language and environment for statistical computing. Austria, Vienna

18.

Frank E, Prien RF, Jarrett RB et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855PubMedCrossRef

19.

Akerblad A-C, Bengtsson F, von Knorring L, Ekselius L (2006) Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 21:117–124PubMedCrossRef

20.

Daniels BA, Kirkby KC, Hay DA et al (1998) Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 32:281–286PubMedCrossRef

21.

Leon AC, Solomon DA, Mueller TI et al (2003) A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 160:727–733PubMedCrossRef

22.

Copeland JR (1983) Psychotic and neurotic depression: discriminant function analysis and five-year outcome. Psychol Med 13:373–383PubMedCrossRef

23.

Culpepper L (2010) Why do you need to move beyond first-line therapy for major depression? J Clin Psychiatry 71(Suppl 1):4–9. doi:10.4088/JCP.9104su1c.01 PubMedCrossRef

24.

Zarate CA Jr, Tohen M (2004) Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 161:169–171PubMedCrossRef

25.

Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520–532. doi:10.1016/j.euroneuro.2009.04.003 PubMedCrossRef

26.

Bernardo AC, Forchuk C (2001) Factors associated with readmission to a psychiatric facility. Psychiatr Serv 52:1100–1102PubMedCrossRef

27.

Havassy BE, Hopkin JT (1989) Factors predicting utilization of acute psychiatric inpatient services by frequently hospitalized patients. Hosp Community Psychiatry 40:820–823PubMed

28.

Labbate LA, Doyle ME (1997) Recidivism in major depressive disorder. Psychother Psychosom 66:145–149PubMedCrossRef

29.

Solomon DA, Leon AC, Mueller TI et al (2005) Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 66:283–290PubMedCrossRef

30.

Robinson OJ, Sahakian BJ (2008) Recurrence in major depressive disorder: a neurocognitive perspective. Psychol Med 38:315–318. doi:10.1017/S0033291707001249 PubMedCrossRef

31.

Thase ME (2006) Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 11:12–21PubMed

32.

Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40PubMedCrossRef

33.

Nierenberg AA, Husain MM, Trivedi MH et al (2009) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40:1–10

Title: Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors
Authors: Florian Seemüller
Sebastian Meier
Michael Obermeier
Richard Musil
Michael Bauer
Mazda Adli
Klaus Kronmüller
Florian Holsboer
Peter Brieger
Gerd Laux
Wolfram Bender
Isabella Heuser
Joachim Zeiler
Wolfgang Gaebel
Michael Riedel
Peter Falkai
Hans-Jürgen Möller
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2014
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-014-0495-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Increased neural activity during overt and continuous semantic verbal fluency in major depression: mainly a failure to deactivate

Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression

Impact of adolescent GluA1 AMPA receptor ablation in forebrain excitatory neurons on behavioural correlates of mood disorders

Suicidality in the prospective Zurich study: prevalence, risk factors and gender

Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients

The effects of exercise on oxidative stress (TBARS) and BDNF in severely depressed inpatients